Introduction {#tca13526-sec-0006}
============

Lung cancer is the global leading cause of cancer‐related mortality, and non‐small cell lung cancer (NSCLC) accounts for \>80% of lung cancers.[^1^](#tca13526-bib-0001){ref-type="ref"}, [^2^](#tca13526-bib-0002){ref-type="ref"} Epidermal growth factor receptor (EGFR) mutations are key driver mutations in NSCLC, and patients with these mutations can be effectively treated using EGFR tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, erlotinib, afatinib, and osimertinib.[^3^](#tca13526-bib-0003){ref-type="ref"}, [^4^](#tca13526-bib-0004){ref-type="ref"}, [^5^](#tca13526-bib-0005){ref-type="ref"}, [^6^](#tca13526-bib-0006){ref-type="ref"}, [^7^](#tca13526-bib-0007){ref-type="ref"}, [^8^](#tca13526-bib-0008){ref-type="ref"}, [^9^](#tca13526-bib-0009){ref-type="ref"}, [^10^](#tca13526-bib-0010){ref-type="ref"} Clinical studies have indicated that EGFR‐TKI treatment provided an overall response rate (ORR) of 60%--80%, although approximately 10% of patients will have progressive disease.[^3^](#tca13526-bib-0003){ref-type="ref"}, [^4^](#tca13526-bib-0004){ref-type="ref"}, [^5^](#tca13526-bib-0005){ref-type="ref"}, [^6^](#tca13526-bib-0006){ref-type="ref"}, [^7^](#tca13526-bib-0007){ref-type="ref"}, [^8^](#tca13526-bib-0008){ref-type="ref"}, [^9^](#tca13526-bib-0009){ref-type="ref"}, [^10^](#tca13526-bib-0010){ref-type="ref"} In addition, recent studies have demonstrated that immune checkpoint inhibitors had low efficacy in patients with *EGFR* mutations.[^11^](#tca13526-bib-0011){ref-type="ref"}, [^12^](#tca13526-bib-0012){ref-type="ref"} Therefore, it is important to identify patients who are expected to experience limited or no response to EGFR‐TKI treatment.

Most patients with NSCLC are diagnosed at an advanced or inoperable stage, with these cases often involving weight loss and a systemic inflammatory response, which reflects cancer cachexia.[^13^](#tca13526-bib-0013){ref-type="ref"}, [^14^](#tca13526-bib-0014){ref-type="ref"} The Glasgow prognostic score (GPS) is a systemic inflammation‐based scoring system that combines serum concentrations of C‐reactive protein (CRP) and albumin used as markers.[^13^](#tca13526-bib-0013){ref-type="ref"}, [^14^](#tca13526-bib-0014){ref-type="ref"} In this context, CRP is a nonspecific inflammation marker that can also be used to identify a poor nutritional status and a risk of poor overall survival,[^15^](#tca13526-bib-0015){ref-type="ref"}, [^16^](#tca13526-bib-0016){ref-type="ref"}, [^17^](#tca13526-bib-0017){ref-type="ref"} while albumin is a nutritional marker that is inversely correlated with CRP.[^18^](#tca13526-bib-0018){ref-type="ref"} The GPS is reportedly a better prognostic factor than performance status among patients with NSCLC,[^19^](#tca13526-bib-0019){ref-type="ref"} and the GPS can be used to predict overall survival (OS) among patients receiving chemotherapy for NSCLC.[^20^](#tca13526-bib-0020){ref-type="ref"}, [^21^](#tca13526-bib-0021){ref-type="ref"}, [^22^](#tca13526-bib-0022){ref-type="ref"}, [^23^](#tca13526-bib-0023){ref-type="ref"} However, there is limited information regarding the association between the GPS and the response to EGFR‐TKI treatment. Therefore, this study evaluated whether the GPS could predict the response to EGFR‐TKI treatment in patients with *EGFR*‐mutated NSCLC.

Methods {#tca13526-sec-0007}
=======

Patients {#tca13526-sec-0008}
--------

This retrospective study protocol was approved by the institutional review board of Gunma University Hospital (no. 1528), and complied with the Declaration of Helsinki. The requirement for informed consent was waived based on the retrospective design. This study evaluated consecutive patients with histologically or cytologically diagnosed NSCLC, who harbored *EGFR* mutations and started EGFR‐TKI monotherapy between October 2006 and December 2016 at the Gunma University Hospital, Gunma Prefectural Cancer Center, and Hidaka Hospital.

Pretreatment values were used for the CRP and albumin concentrations, and the GPS values were defined as a GPS of 0 (CRP of \<10 mg/L and albumin of \>35 g/L), a GPS of 1 (CRP of ≥10 mg/L or albumin of \<35 g/L), or a GPS of 2 (CRP of \>10 mg/L and albumin of \<35 g/L). For the present study, we defined gefitinib and erlotinib as first generation EGFR‐TKIs, and afatinib as a second generation EGFR‐TKI.

Adverse events were graded using the Common Terminology Criteria for Adverse Events (version 4.0), and the objective tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).[^24^](#tca13526-bib-0024){ref-type="ref"} The median follow‐up duration for censored cases was 30.2 months (range: 0.4--97.2 months).

Statistical analysis {#tca13526-sec-0009}
--------------------

Continuous variables were analyzed using the Student\'s *t*‐test and categorical variables were analyzed using the χ2 test. The relationships between different variables or matched pairs were examined using the nonparametric Spearman rank test or Wilcoxon signed‐rank test, as appropriate. The Kaplan‐Meier method and log‐rank test were used to compare the survival outcomes. The PFS interval was calculated from the start of EGFR‐TKI treatment to the first instance of disease relapse, death, or the last follow‐up visit (in cases with no evidence of relapse). The OS interval was calculated from the start of EGFR‐TKI treatment to death from any cause. Univariate and multivariate analyses of survival were also performed using Cox proportional hazard models. Differences were considered statistically significant at *P*‐values of \<0.05, and all analyses were performed using JMP Pro software (version 12.0; SAS Institute Inc., Cary, NC, USA).

Results {#tca13526-sec-0010}
=======

Patient characteristics {#tca13526-sec-0011}
-----------------------

A total of 238 advanced NSCLC patients who had *EGFR* mutations were screened between October 2006 and December 2016. Among them, 10 patients had not received EGFR‐TKI monotherapy and pretreatment albumin, and CRP values were missing in seven patients each. Therefore, 214 patients were included for further analysis (Fig [1](#tca13526-fig-0001){ref-type="fig"}). The characteristics of the 214 patients (83 males and 131 females) are shown in Table [1](#tca13526-tbl-0001){ref-type="table"}. The median age at the start of EGFR‐TKI treatment was 69 years (range: 39--92 years) and 76 patients were smokers. The Eastern Cooperative Oncology Group performance status (ECOG PS) scores were 0--1 for 168 patients, two for 33 patients, three for eight patients, and four for five patients. The predominant histological type was adenocarcinoma (212 patients), although one patient had poorly differentiated carcinoma and one patient had the "not otherwise specified" histological type. The *EGFR* mutation subtypes were exon 19 deletions (107 patients), L858R (98 patients), and various other mutations (six patients had G719X, two patients had L861Q, and one patient had an exon 19 deletion plus L858R). Three patients had de novo T790M mutations and 17 patients developed T790M mutations during their treatment course. All patients received EGFR‐TKI monotherapy, which included gefitinib (144 patients), erlotinib (33 patients), and afatinib (37 patients). The GPS values at the start of EGFR‐TKI treatment were 0 (141 patients), one (43 patients), and two (30 patients). Box plots showing the CRP, albumin, and body mass index distributions in the three GPS groups are shown in Fig [2](#tca13526-fig-0002){ref-type="fig"}. The ECOG‐PS and GPS values were significantly correlated (*P* \< 0.01).

![Flow chart of patient enrollment.](TCA-11-2188-g001){#tca13526-fig-0001}

###### 

Patient characteristics

                                                    All patients   GPS score                             
  ------------------ ------------------------------ -------------- ------------- ----------- ----------- --------
  Age                \<65 years/≥65 years           62/152         44/97         10/33       8/22          0.57
  Sex                Male/Female                    83/131         51/90         18/25       14/16         0.50
  Stage              I/II/III/IV                    23/5/26/160    16/4/21/100   5/0/3/35    2/1/2/25      0.51
  Smoking status     Ever/never                     76/138         45/96         17/26       14/16         0.25
  ECOG‐PS            0--1/2/3/4                     168/33/8/5     126/12/2/1    30/10/2/1   12/11/4/3    \<0.01
  Histology          Ad/non‐Ad                      212/2          140/1         43/0        29/1          0.30
  *EGFR* mutation    Ex19del/L858R/other            107/98/9       76/61/4       19/21/3     12/16/2       0.43
  T790M mutation     Positive/negative or unknown   17/197         13/128        4/39        0/30          0.22
  EGFR‐TKI           Gefitinib/erlotinib/afatinib   144/33/37      92/20/29      27/10/6     25/3/2        0.14
  Line of EGFR‐TKI   1/2/≥3                         163/41/10      109/26/6      31/8/4      23/7/0        0.42

Ad, adenocarcinoma; ECOG‐PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; TKI, tyrosine kinase inhibitor.

![Box plot of the C‐reactive protein and albumin distributions in the Glasgow prognostic score groups.](TCA-11-2188-g002){#tca13526-fig-0002}

Survival analysis {#tca13526-sec-0012}
-----------------

The overall median PFS was 11.3 months (95% confidence interval \[CI\]: 1.2--40.2 months) and 190 patients experienced disease progression. Table [2](#tca13526-tbl-0002){ref-type="table"} shows the results of the univariate and multivariate analyses of PFS, which revealed significant associations with ECOG‐PS, type of EGFR‐TKI, and GPS. Multivariate analyses revealed that poor PFS was associated with a high ECOG‐PS (hazard ratio \[HR\]: 2.22, *P* \< 0.01), first generation EGFR‐TKI treatment (HR: 1.55, *P* = 0.03), and a GPS of 2 (HR 1.66, *P* = 0.03). The Kaplan‐Meier curves for PFS are shown in Fig [3](#tca13526-fig-0003){ref-type="fig"}; a GPS of 0--1 was associated with significantly longer PFS than a GPS of 2 (*P* \< 0.01).

###### 

Univariate and multivariate analyses of progression‐free and overall survival

  Characteristic     Subgroups                         HR for PFS (95% CI)   HR for OS (95% CI)                                                                                 
  ------------------ --------------------------------- --------------------- -------------------- ------------------- -------- ------------------- -------- ------------------- --------
  Age                \<65 years/≥65 years              1.16 (0.84--1.58)     0.33                                              0.86 (0.58--1.23)   0.41                         
  Sex                Male/Female                       1.15 (0.85--1.54)     0.33                                              1.42 (1.00--1.99)   0.04     1.08 (0.71--1.64)   0.68
  Smoking status     Ever/never                        1.12 (0.82--1.51)     0.44                                              1.53 (1.08--2.15)   0.01     1.59 (1.04--2.43)   0.03
  ECOG‐PS            2--4/0--1                         2.82 (1.96--3.98)     \<0.01                2.22 (1.48--3.28)   \<0.01  4.12 (2.75--6.07)   \<0.01   3.46 (2.15--5.47)   \<0.01
  Line of EGFR‐TKI   1/≥2                              0.97 (0.70--1.36)     0.87                                              0.94 (0.65--1.39)   0.76                         
  EGFR‐TKI           Gefitinib or erlotinib/afatinib   1.75 (1.17--2.74)     \<0.01                1.55 (1.03--2.43)    0.03   1.75 (1.04--3.20)   0.03     1.39 (0.81--2.57)   0.23
  *EGFR* mutation    Ex19del or L858R/other            0.55 (0.30--1.17)     0.11                                              0.46 (0.23--1.11)   0.08                         
  T790M mutation     Yes/No or unknown                 0.86 (0.50--1.38)     0.56                                              0.42 (0.19--0.81)   \<0.01   0.54 (0.24--1.06)   0.07
  GPS score          2/0--1                            2.44 (1.58--3.63)     \<0.01                1.66 (1.03--2.61)    0.03   3.59 (2.22--5.60)   \<0.01   1.77 (1.03--2.97)   0.03

CI, confidence interval; ECOG‐PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.

![Kaplan‐Meier curves for (**a**) progression‐free survival (PFS) (![](TCA-11-2188-g004.jpg "image")) 0--1, (![](TCA-11-2188-g005.jpg "image")) 2 and (**b**) overall survival (OS) according to the Glasgow prognostic score (GPS) (![](TCA-11-2188-g006.jpg "image")) 0--1, (![](TCA-11-2188-g007.jpg "image")) 2. Solid lines indicate a post‐treatment GPS of 0--1 and dashed lines indicate a post‐treatment GPS of 2.](TCA-11-2188-g003){#tca13526-fig-0003}

The median OS in all patients was 27.8 months (95% CI: 2.4--85.0 months) and 137 patients ultimately died. Table [2](#tca13526-tbl-0002){ref-type="table"} shows the results of the univariate and multivariate analyses of OS, which revealed significant associations with sex, smoking status, ECOG‐PS, type of EGFR‐TKI, T790M status, and the GPS. Multivariate analyses revealed that poor OS was associated with past smoking (HR: 1.59, *P* = 0.03), a high ECOG‐PS (HR: 3.46, *P* \< 0.01), and a GPS of 2 (HR: 1.77, *P* = 0.03) (Table [2](#tca13526-tbl-0002){ref-type="table"}). The Kaplan‐Meier curves for OS are shown in Fig [3](#tca13526-fig-0003){ref-type="fig"}; a GPS of 0--1 was associated with significantly longer OS than a GPS of 2 (*P* \< 0.01).

Among patients with an ECOG‐PS of 0--1, multivariate analysis revealed that a poor PFS was associated with first generation EGFR‐TKIs (HR: 1.69, *P* = 0.01) and a GPS of 2 (HR: 2.51, *P* = 0.01) (Table [3](#tca13526-tbl-0003){ref-type="table"}). Univariate analyses revealed that OS was associated with smoking, T790M status, and GPS. Multivariate analysis revealed that poor OS was independently associated with past smoking (HR: 1.61, *P* = 0.02) and a GPS of 2 (HR: 3.00, *P* \< 0.01) (Table [3](#tca13526-tbl-0003){ref-type="table"}). There were no independent predictors of PFS or OS among patients with an ECOG‐PS of ≥2 (Table [S1](#tca13526-supitem-0001){ref-type="supplementary-material"}).

###### 

Univariate and multivariate analyses of progression‐free and overall survival for performance status of 0--1

  Characteristic     Subgroups                         HR for PFS (95% CI)   HR for OS (95% CI)                                                                               
  ------------------ --------------------------------- --------------------- -------------------- ------------------- ------ ------------------- -------- ------------------- --------
  Age                \<65 years/≥65 years              1.20 (0.83--1.70)     0.30                                            0.84 (0.53--1.28)   0.43                         
  Sex                Male/Female                       1.02 (0.72--1.42)     0.89                                            1.33 (0.88--2.00)   0.16                         
  Smoking status     Ever/never                        1.10 (0.78--1.54)     0.56                                            1.70 (1.13--2.55)   0.01      1.61 (1.07--2.42)    0.02
  Line of EGFR‐TKI   1/≥2                              1.08 (0.73--1.63)     0.69                                            1.11 (0.69--1.84)   0.66                         
  EGFR‐TKI           Gefitinib or erlotinib/afatinib   1.59 (1.04--2.56)     0.03                  1.69 (1.10--2.73)   0.01  1.45 (0.81--2.83)   0.21                         
  *EGFR* mutation    Ex19del or L858R/other            0.55 (0.27--1.31)     0.16                                            0.46 (0.20--1.33)   0.14                         
  T790M mutation     Yes/no or unknown                 1.03 (0.59--1.69)     0.88                                            0.47 (0.19--0.95)   0.03      0.52 (0.21--1.05)    0.07
  GPS score          2/0--1                            2.24 (1.13--3.98)     0.02                  2.51 (1.26--4.49)   0.01  3.42 (1.58--6.58)   \<0.01    3.00 (1.38--5.78)   \<0.01

CI, confidence interval; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.

Among patients who were treated in the first‐line setting, univariate analysis revealed that PFS was associated with ECOG‐PS, type of EGFR‐TKI, and GPS. Multivariate analysis revealed that poor PFS was independently associated with ECOG‐PS of ≥2 (HR: 2.58, *P* \< 0.01), and first generation EGFR‐TKIs (HR: 1.65, *P* = 0.01) (Table [4](#tca13526-tbl-0004){ref-type="table"}). Univariate analysis revealed that OS was associated with ECOG‐PS, type of EGFR‐TKI, T790M status, and GPS. Multivariate analysis revealed that poor OS was independently associated with an ECOG‐PS of ≥2 (HR: 3.31, *P* \< 0.01), and a GPS of 2 (HR: 2.24, *P* = 0.01) (Table [4](#tca13526-tbl-0004){ref-type="table"}). Among patients who were treated beyond the second‐line, only ECOG‐PS ≥2 was associated with poor PFS (HR: 0.43, *P* = 0.01) ([Table S2](#tca13526-supitem-0001){ref-type="supplementary-material"}). Univariate analysis revealed that OS was associated with sex, smoking, ECOG‐PS, and type of *EGFR* mutation. Multivariate analysis revealed that only ECOG‐PS ≥2 was associated with poor OS (HR: 3.98, *P* \< 0.01) ([Table S2](#tca13526-supitem-0001){ref-type="supplementary-material"}).

###### 

Univariate and multivariate analyses of progression‐free and overall survival with first‐line setting

  Characteristic    Subgroups                         HR for PFS (95% CI)   HR for OS (95% CI)                                                                                 
  ----------------- --------------------------------- --------------------- -------------------- ------------------- -------- ------------------- -------- ------------------- --------
  Age               \<65/≥65 years                    1.09 (0.74--1.56)     0.64                                              0.82 (0.51--1.28)   0.40                         
  Sex               Male/Female                       1.02 (0.72--1.43)     0.89                                              1.17 (0.77--1.75)   0.44                         
  Smoking status    Ever/never                        1.19 (0.83--1.68)     0.33                                              1.40 (0.93--2.09)   0.10                         
  ECOG‐PS           2--4/0--1                         3.39 (2.12--5.23)     \<0.01                2.58 (1.49--4.31)   \<0.01  4.77 (2.87--7.68)   \<0.01    3.31(1.83--5.79)    \<0.01
  EGFR‐TKI          Gefitinib or erlotinib/afatinib   1.82 (1.19--2.90)     \<0.01                1.65 (1.08--2.65)    0.01   1.87 (1.07--3.54)   0.02      1.61 (0.92--3.07)    0.09
  *EGFR* mutation   Ex19del or L858R/other            067 (0.34--1.59)      0.34                                              0.60 (0.26--1.71)   0.30                         
  T790M mutation    Yes/No or unknown                 0.86 (0.49--1.40)     0.57                                              0.45 (0.19--0.92)   0.02      0.55 (0.23--1.12)    0.10
  GPS score         2/0--1                            2.42 (1.46--3.83)     \<0.01                1.52 (0.84--2.64)    0.15   4.15 (2.37--6.92)   \<0.01    2.24 (1.17--4.14)    0.01

CI, confidence interval; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.

There were 132 of the 214 (61.7%) patients who exhibited an objective clinical response to EGFR‐TKIs. Only an ECOG‐PS of 0--1 was associated with treatment response (odds ratio: 3.28, *P* \< 0.01) ([Table S3](#tca13526-supitem-0001){ref-type="supplementary-material"}).

Discussion {#tca13526-sec-0013}
==========

To the best of our knowledge, this is the first study to examine the relationship between the GPS and the efficacy of EGFR‐TKI treatment. Multivariate analyses revealed that the GPS was independently associated with PFS and OS; this suggests that the GPS may be used to predict the efficacy of EGFR‐TKI treatment for *EGFR*‐mutated NSCLC.

Previous studies have also identified factors that predicted the efficacy of EGFR‐TKI treatment; these included the neutrophil‐to‐lymphocyte ratio and the prognostic nutritional index.[^25^](#tca13526-bib-0025){ref-type="ref"}, [^26^](#tca13526-bib-0026){ref-type="ref"}, [^27^](#tca13526-bib-0027){ref-type="ref"}, [^28^](#tca13526-bib-0028){ref-type="ref"} GPS is a useful marker in clinical practice, as most centers are able to test serum CRP and albumin concentrations, and the GPS calculation was more objective and had greater prognostic value than the ECOG‐PS.[^19^](#tca13526-bib-0019){ref-type="ref"}, [^29^](#tca13526-bib-0029){ref-type="ref"} GPS is also associated with weight and muscle loss, drug metabolism, elevated cytokine and adipokine levels, and poor PS[^14^](#tca13526-bib-0014){ref-type="ref"}, [^30^](#tca13526-bib-0030){ref-type="ref"}, [^31^](#tca13526-bib-0031){ref-type="ref"}, [^32^](#tca13526-bib-0032){ref-type="ref"}, [^33^](#tca13526-bib-0033){ref-type="ref"}, [^34^](#tca13526-bib-0034){ref-type="ref"}, [^35^](#tca13526-bib-0035){ref-type="ref"}, [^36^](#tca13526-bib-0036){ref-type="ref"}; these factors reflect the host\'s nutritional status. This may explain why the GPS could play a predictive role for EGFR‐TKIs. Therefore, it appears reasonable to use the GPS in clinical practice.

Although EGFR‐TKIs are key treatment agents for patients with *EGFR*‐mutated NSCLC, there are some populations who do not show clinical benefit with EGFR‐TKIs. In our analysis, among patients with ECOG‐PS of 0--1, the GPS was able to predict both, PFS and OS. This may suggest that the population with an ECOG‐PS of 0--1 is heterogeneous, and the GPS is useful for prognosis in this population. However, among patients treated in the first‐line setting, the GPS was able to predict OS, but not PFS. This may reflect the fact that patients with good GPS have more chances of receiving subsequent treatments after EGFR‐TKI.

The present study has several limitations. First, the study period precluded an analysis of third generation EGFR‐TKIs, such as osimertinib, which was only approved for use in Japan in 2016. Second, the study sample size was small, and may have introduced selection bias due to the retrospective nature of this study, although patients from three different institutions were included. Third, the study failed to consider other systemic inflammation‐based markers, such as the neutrophil‐to‐lymphocyte ratio. Further prospective studies are needed to overcome these limitations.

In conclusion, the GPS predicted the efficacy of EGFR‐TKI treatment and survival outcomes among NSCLC patients with *EGFR* mutations. Although further studies are needed to validate our findings, the GPS is an easily calculated biomarker, which might be ideal for routine clinical use in this setting.
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